Disposition of tricyclic nucleoside-5'-monophosphate in blood and plasma of patients during phase I and II clinical trials.
Tricyclic nucleoside-5'-monophosphate (TCN-P) and its dephosphorylated metabolite tricyclic nucleoside (TCN) have been measured in the blood and plasma of patients receiving TCN-P by rapid iv infusion in a phase I trial at daily doses of 24-55 mg/m2 for 5 days and in patients receiving TCN-P in a phase II trial at a single dose of 250 mg/m2. TCN-P was rapidly accumulated by rbcs and had an initial half-life in blood of 6.1 hours and a terminal half-life of 89.2 hours. Total-body blood clearance of TCN-P was 2.6 ml/minute/m2. The concentration of TCN-P in blood was not related to the dose of TCN-P and did not increase over 5 days' administration in the phase I patients. Plasma contained little detectable TCN-P even 5 minutes after administration. Plasma contained low concentrations of TCN, up to 0.4 microgram/ml, which were maintained over several days. TCN did not accumulate in the plasma with repeated administration of TCN-P in the phase I patients. No other metabolites of TCN-P, apart from TCN, were detected in blood or plasma. No relationship was detected between pharmacokinetics and toxic response of TCN-P in the phase II patients.
D000073:Acenaphthenes; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000097:blood*; D004341:Drug Evaluation; D004912:Erythrocytes / Q000378:metabolism; D006207:Half-Life; D006801:Humans; D007700:Kinetics; D009369:Neoplasms / Q000097:blood / Q000188:drug therapy*; D012265:Ribonucleotides / Q000009:adverse effects / Q000097:blood*
D000073:Acenaphthenes; D000970:Antineoplastic Agents; D012265:Ribonucleotides; C014205:triciribine phosphate